Ken Griffin’s Burning Rock Biotech BNR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$285K Buy
+17,669
New +$463K ﹤0.01% 10585
2025
Q3
Sell
-24,451
Closed -$77.3K 12794
2025
Q2
$77.3K Buy
+24,451
New +$75.9K ﹤0.01% 11519
2025
Q1
Sell
-12,267
Closed -$82.8K 14512
2024
Q4
$82.8K Buy
+12,267
New +$56.5K ﹤0.01% 11746
2024
Q2
Sell
-1,256
Closed -$9.16K 14286
2024
Q1
$9.16K Buy
+1,256
New +$10.5K ﹤0.01% 13517
2022
Q4
Sell
-2,601
Closed -$63K 14883
2022
Q3
$63K Buy
+2,601
New +$83.9K ﹤0.01% 11456
2022
Q2
Sell
-2,875
Closed -$267K 12908
2022
Q1
$267K Sell
2,875
-12,185
-81% -$1.06M ﹤0.01% 10849
2021
Q4
$1.44M Buy
15,060
+11,729
+352% +$1.61M ﹤0.01% 6987
2021
Q3
$596K Sell
3,331
-487
-13% -$108K ﹤0.01% 9432
2021
Q2
$1.13M Sell
3,818
-6,780
-64% -$2.01M ﹤0.01% 8058
2021
Q1
$2.85M Buy
+10,598
New +$3.23M ﹤0.01% 5560
2020
Q3
Sell
-2,000
Closed -$540K 10084
2020
Q2
$540K Buy
+2,000
New +$548K ﹤0.01% 6933

Other funds holding BNR

Ken Griffin's BNR Position: Q1 2026 in Review

Ken Griffin opened a new position in Burning Rock Biotech (BNR) in Q1 2026: 17,669 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #10585 among its holdings. This is a return to the name: Ken Griffin previously reported a position in BNR as recently as Q2 2025.

Ken Griffin first reported a position in BNR in Q2 2020 and has held it in 11 quarters since. The position peaked at $2.85M in Q1 2021. 16 funds tracked by Wall St. Rank hold BNR as of Q1 2026.

  • Ken Griffin held 17,669 shares of Burning Rock Biotech worth $285K as of Q1 2026.
  • Burning Rock Biotech was a new Ken Griffin position in Q1 2026.
  • Burning Rock Biotech made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10585 holding.
  • Ken Griffin first reported a position in Burning Rock Biotech in Q2 2020 and has held it in 11 quarters since.
  • Ken Griffin's Burning Rock Biotech position peaked at $2.85M in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.